Osteoporosis International

, Volume 23, Issue 3, pp 1069–1074 | Cite as

Impact of bone turnover markers and/or educational information on persistence to oral bisphosphonate therapy: a community setting-based trial

  • S. L. Silverman
  • K. Nasser
  • S. Nattrass
  • B. Drinkwater
Original Article



We examined how the use of bone turnover markers and educational information affects persistence of bisphosphonate use in osteoporotic patients. We found that reporting bone turnover results and/or educational information did not affect persistence.


Long-term adherence and persistence to osteoporosis medication are poor. We examined whether reporting of bone turnover marker results, education about osteoporosis, or a combination of both would increase persistence to oral bisphosphonates.


Two hundred and forty women who were 5 years postmenopausal with BMD at least 2.0 standard deviations below normal were recruited for the study. All women were given a new prescription for alendronate and randomly assigned to one of four groups: (1) bone marker results at baseline, 3 and 12 months; (2) educational materials every month and a membership in the National Osteoporosis Foundation; (3) bone marker and educational information; and (4) control, no information other than usual care. Persistence among randomization groups was tested using survival analysis adjusting for the delay between intervention methods.


Of those filling their initial prescription, 95.5% refilled their prescription at the end of the first month, 87% at 3 months, 82% at 6 months, and 78% at 10 months. Overall persistence through 12 months was 54%. There was no difference found among the four groups for persistence time using (p > 0.58).


Providing bone turnover marker results is not an effective way to enhance early compliance and persistence with drug therapy. While the women in our study felt that bone marker results and educational information were helpful to them, there was no difference in persistence between those who received either bone marker information and/or educational information and those who did not. Because of the unexpected rate of primary nonadherence, this study may be underpowered.


Adherence Bone turnover markers N-Telopeptide Osteoporosis Persistence 


  1. 1.
    Silverman S, Schein JR (2001) Physician-patient decision making in osteoporosis management. J Musculoskel Med 18:124–130Google Scholar
  2. 2.
    Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82(12):1493–1501PubMedCrossRefGoogle Scholar
  3. 3.
    Rubin SM, Cummings SR (1992) Results of bone density information affect women’s decisions about taking measures to prevent fractures. Ann Intern Med 116:990–995PubMedGoogle Scholar
  4. 4.
    Silverman S, Drinkwater B (1997) Effect of bone density information on decision making about estrogen. Obstet Gynecol 89:321–325PubMedCrossRefGoogle Scholar
  5. 5.
    Cummings SR, Palermo L, Browner W et al (2000) Monitoring osteoporosis therapy with bone densitometry: Misleading changes and regression to mean. JAMA 283:1318PubMedCrossRefGoogle Scholar
  6. 6.
    Papanioannou A, Parkinson W, Adachi J et al (1998) Women’s decisions about taking measures to prevent fractures. Can Med Assoc J 15(10):1253–1257Google Scholar
  7. 7.
    Gleeson T, Iversen MD, Avorn J, Brookhart AM, Katz JN, Losina E, May F, Patrick AR, Shrank WH, Solomon DH (2009) Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int 20:2127–2134. doi:10.1007/s00198-009-0976-0 PubMedCrossRefGoogle Scholar
  8. 8.
    Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117–1123PubMedCrossRefGoogle Scholar
  9. 9.
    Delmas PD, Vrijens B, Eastell R, Roux C, Pols HA, Ringe JD, Grauer A, Cahall D, Watts NB, Improving Measurements of Persistence on Actonel Treatment (IMPACT) Investigators (2007) Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92:1296–1304PubMedCrossRefGoogle Scholar
  10. 10.
    Physician’s guide to prevention and treatment of osteoporosis (2003) National Osteoporosis Foundation; Washington D.C.Google Scholar
  11. 11.
    Fraenkel L, Gulanski B, Wittink D (2007) Patient willingness to take teriparatide. Patient Educ Couns 65(2):237–244PubMedCrossRefGoogle Scholar
  12. 12.
    Ratcliffe J, Buxton M, McGarry T, Sheldon R, Chancellor J (2004) Patients’ preferences for characteristics associated with treatments for osteoarthritis. Rheumatology 43:337–345PubMedCrossRefGoogle Scholar
  13. 13.
    Potts M, Weinberger M, Brandy KD (1984) Views of patients and providers regarding the importance of various aspects of an arthritis treatment program. J Rheumatol 11:71–75PubMedGoogle Scholar
  14. 14.
    Fraenkel L, Gulanski B, Wittink D (2006) Patient treatment preferences for osteoporosis. Arthritis Rheum 55(5):729–735PubMedCrossRefGoogle Scholar
  15. 15.
    Rabenda V, Mertens R, Fabri V et al (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19:811–818. doi:10.1007/s00198-007-0506-x PubMedCrossRefGoogle Scholar
  16. 16.
    Weycker D, Macarios D, Edelsberg J, Oster G (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17:1645–1652. doi:10.1007/s00198-006-0179-x PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2011

Authors and Affiliations

  • S. L. Silverman
    • 1
    • 2
  • K. Nasser
    • 2
  • S. Nattrass
    • 3
  • B. Drinkwater
    • 3
  1. 1.UCLA/Cedars-SinaiLos AngelesUSA
  2. 2.Osteoporosis Medical CenterBeverly HillsUSA
  3. 3.Puget Sound Osteoporosis CenterSeattleUSA

Personalised recommendations